30 Day Trial

Anika Therapeutics Posts 1Q17 Orthobiologic Revenue

Share:

Anika Therapeutics posted 1Q17 orthobiologic revenue of US $20.2MM, +3.3% vs. 1Q16. 

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.